| Stock Name | 一脉阳光 |
|---|---|
| Stock Code | 02522 |
| Company Full Name | 一脉阳光 |
| Industry | 醫療保健 |
| Principal Activities | 公司是中國一家領先的醫學影像專科醫療集團，為整個醫學影像產業鏈提供多元化影像服務及價值的醫學影像平臺運營商及管理者。 |
| Listing Date | 2024-06-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市朝陽區民族園路2號2幢 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.rimag.com.cn/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 14.98 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 45.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 133,441,840 |
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 7,490 |
| 2 lots | 1,000 | HK$ 14,980 |
| 3 lots | 1,500 | HK$ 22,470 |
| 4 lots | 2,000 | HK$ 29,960 |
| 5 lots | 2,500 | HK$ 37,450 |
| 6 lots | 3,000 | HK$ 44,940 |
| 7 lots | 3,500 | HK$ 52,430 |
| 8 lots | 4,000 | HK$ 59,920 |
| 9 lots | 4,500 | HK$ 67,410 |
| 10 lots | 5,000 | HK$ 74,900 |
| 12 lots | 6,000 | HK$ 89,880 |
| 14 lots | 7,000 | HK$ 104,860 |
| 16 lots | 8,000 | HK$ 119,840 |
| 18 lots | 9,000 | HK$ 134,820 |
| 20 lots | 10,000 | HK$ 149,800 |
| 30 lots | 15,000 | HK$ 224,700 |
| 40 lots | 20,000 | HK$ 299,600 |
| 50 lots | 25,000 | HK$ 374,500 |
| 60 lots | 30,000 | HK$ 449,400 |
| 70 lots | 35,000 | HK$ 524,300 |
| 80 lots | 40,000 | HK$ 599,200 |
| 90 lots | 45,000 | HK$ 674,100 |
| 100 lots | 50,000 | HK$ 749,000 |
| 120 lots | 60,000 | HK$ 898,800 |
| 140 lots | 70,000 | HK$ 1,048,600 |
| 160 lots | 80,000 | HK$ 1,198,400 |
| 180 lots | 90,000 | HK$ 1,348,200 |
| 200 lots | 100,000 | HK$ 1,498,000 |
| 300 lots | 150,000 | HK$ 2,247,000 |
| 400 lots | 200,000 | HK$ 2,996,000 |
| 500 lots | 250,000 | HK$ 3,745,000 |
| 600 lots | 300,000 | HK$ 4,494,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 700 lots | 350,000 | HK$ 5,243,000 |
| 800 lots | 400,000 | HK$ 5,992,000 |
| 900 lots | 450,000 | HK$ 6,741,000 |
| 1,000 lots | 500,000 | HK$ 7,490,000 |
| 1,200 lots | 600,000 | HK$ 8,988,000 |
| 1,400 lots | 700,000 | HK$ 10,486,000 |
| 1,600 lots | 800,000 | HK$ 11,984,000 |
| 1,782 lots | 891,000 | HK$ 13,347,180 |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 15.0 |
|---|---|
| First Day Open | HK$ 15.0 |
| First Day Change | 0.13% |
| First Day Volume | 12268300.0 |
| First Day Turnover | 185911000.0 |
| Use of Proceeds | 1、約50.0%或111.9百萬港元，用于擴充醫學影像中心網絡； 2、約20.0%或44.8百萬港元，用于在醫學影像領域尋求戰略合作及并購的機會以及在醫療影像服務產業鏈中尋求戰略合作及投資機會； 3、約20.0%或44.8百萬港元，用于將業務拓展至(i)相對缺乏醫療資源的海外國家和地區；及(ii)人均可支配收入高以及在醫療影像服務方面具有龐大增長潛力的海外國家和地區； 4、約10.0%或22.4百萬港元，用作營運資金及一般公司用途。 |
|---|
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 联影医疗科技香港有限公司 | 11,998,980 HKD | — | 4.50% | — | 6 months | 2024-12-07 |
| 2 | 中国新锐医药控股有限公司 | 11,998,980 HKD | — | 4.50% | — | 6 months | 2024-12-07 |
| 3 | 卓投企业管理(香港)有限公司 | 96,029,290 HKD | — | 35.98% | — | 6 months | 2024-12-07 |
| Chairman | 陳朝陽 |
|---|---|
| Company Secretary | 何英飛;張瀟 |
| Major Shareholders & Holdings | 南昌一脈陽光企業管理中心(有限合伙)(16.58%);王世和(4.98%);顧軍軍(4.98%) |
|---|
Market Sentiment
The 336x oversubscription ratio reflects intense retail enthusiasm for this healthcare AI offering, likely bolstered by clawback reallocation that boosted the public tranche. A hit rate of 30.3% is relatively generous for such demand, allowing many small investors to obtain partial lots. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
A notable tier anomaly exists: the A-tail tier (250,000 shares) expects 0.6154 lots, nearly matching the B-head tier (300,000 shares, 0.7023 lots), indicating marginal allocation gain for a 20% larger application. This compression suggests poor broker fee efficiency for those barely entering margin financing, as the incremental capital yields minimal extra shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Mainland Chinese applicants comprised 78.3% of the holder base, signaling strong domestic demand and brand recognition for the company. The gender split is virtually even (49.8% male), and the average investor age of 46 points to a mature, experienced demographic. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
